Repligen Corporation has completed its previously announced acquisition of BioLife Solutions, Inc. The transaction was finalized on October 6, 2026, pursuant to an Agreement and Plan of Merger dated July 21, 2026. Under the terms of the agreement, BioLife ceased to exist as a separate legal entity and became a wholly owned subsidiary of Repligen.
In connection with the closing, BioLife stockholders received a total consideration of $11.25 in cash and 0.1442 shares of Repligen common stock for each share of BioLife common stock held. The merger consideration was paid without interest, and stockholders received cash in lieu of any fractional shares of Repligen common stock. Additionally, all outstanding BioLife options, restricted stock units, and restricted stock were accelerated and converted into the right to receive the merger consideration.
Following the completion of the mergers, BioLife notified Nasdaq that it no longer fulfills the exchange’s listing requirements. Consequently, BioLife Common Stock will be delisted from the Nasdaq Capital Market. BioLife intends to file a certification with the SEC to deregister its shares and cease its obligations as a public company.
Repligen stated that BioLife’s products are deeply embedded in the cell therapy workflow and are complementary to its existing offerings. The company noted that BioLife’s differentiated biopreservation media portfolio, led by CryoStor, supports 18 commercially approved therapies and the majority of U.S. cell-based therapy trials. Repligen intends to provide further details regarding the transaction’s impact on its 2026 financial outlook during its upcoming third-quarter earnings call.
